Long-term anakinra therapy in Schnitzler syndrome: real-world evidence on remission of neutrophilic dermatitis and systemic inflammation, safety, biomarker insights and dose optimization
IntroductionSchnitzler syndrome (SchS) is a rare, late-onset, acquired autoinflammatory disorder characterized by recurrent urticarial lesions, monoclonal gammopathy and systemic inflammation. Although interleukin-1 (IL-1) blockade with anakinra is con…